12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ACU-4429: Interim Phase IIa data

Interim data from the double-blind, U.S. Phase IIa ENVISION Clarity trial in 56 patients showed that once-daily oral ACU-4429 led to dose-dependent inhibition of the visual cycle from baseline to day 14, as measured by extent of suppression of ERG b-rod recovery after 3-minute...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >